Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07652658 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
A Phase 2 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 359
- Enrollment target
NCT07652658: Recruiting Phase 2 study, sponsored by AstraZeneca.
NCT07652658 is a Phase 2 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 359 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (170% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07652658, a Phase 2 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 359 participants
- Enrollment target
Study Summary
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.
Primary Outcome
To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24
Interventions
- OTHER Placebo for AZD8965
- DRUG AZD8965 low dose
- DRUG AZD8965 medium dose
- DRUG AZD8965 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2026-06-11 |
| Est. Completion | 2028-09-14 |
| Phase | Phase 2 |
What NCT07652658 shows while recruiting
NCT07652658 is an interventional study that assigns participants to a tested intervention. The registered 359 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (170% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo for AZD8965 is the first listed.
NCT07652658 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07652658 about?
NCT07652658 is a clinical study titled "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.". This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic...
What is the current status of trial NCT07652658?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 359 participants. The study started on 2026-06-11. Estimated completion is 2028-09-14.
What interventions are being tested in trial NCT07652658?
The interventions under investigation include: Placebo for AZD8965 (OTHER), AZD8965 low dose (DRUG), AZD8965 medium dose (DRUG), AZD8965 high dose (DRUG).
Who is sponsoring clinical trial NCT07652658?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07652658's enrollment target sits among peer trials
359 127th of 2000 higher than 1,874 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05118789 · 359 participants · Phase 1
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI